Chen D, et al. - In patients with refractory epilepsy, researchers tested the safety and effectiveness profile of levetiracetam used as add-on therapy. This meta-analysis included 17 trials with a total of 3,205 participants, including 14 adult trials and 3 pediatric trials. Somnolence, asthenia, dizziness, infection, nasopharyngitis, anxiety, and irritability were significantly higher in patients treated with levetiracetam vs placebo, though these adverse events were mostly considered mild and fleeting. For adults at 1,000–3,000 and children at 60 mg/kg/day, levetiracetam is an effective anti-epileptic drug with a favorable adverse event profile.